Your prediction
ALS Ltd Stock
A very strong showing by ALS Ltd today, with an increase of €0.40 (3.150%) compared to yesterday's price.
Pros and Cons of ALS Ltd in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of ALS Ltd vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| ALS Ltd | 3.150% | -2.308% | -5.224% | 27.638% | 2.419% | 81.429% | 64.935% |
| Seek Ltd | 1.900% | -5.325% | 5.960% | -40.299% | -38.931% | -45.205% | -56.757% |
| Downer EDI Ltd | 0.000% | 0.000% | -2.479% | 27.568% | 6.306% | 74.815% | 42.169% |
| Fti Consulting | 1.450% | -1.429% | 5.344% | -6.757% | -5.479% | -14.286% | 20.000% |
News
Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape
Key Points
- Interested in Amylyx Pharmaceuticals, Inc.? Here are five stocks we like better.
- Amylyx expects Phase 3 topline results for avexitide in Q3 as it advances the drug for
Juno's Vespa Critical Minerals Discovery Expands to Include Heavy Rare Earth Magnet Metals
New Discovery Adds the Metals at the Centre of Global Supply Concerns
TORONTO, ON / ACCESS Newswire / May 19, 2026 / Juno Corp. ("Juno" or the "Company") today announced the discovery of
NRx Pharmaceuticals Q1 Earnings Call Highlights
Key Points
- Interested in NRx Pharmaceuticals, Inc.? Here are five stocks we like better.
- KETAFREE moved closer to a potential summer 2026 approval after the FDA issued mostly minor review